Who Paid My Doc
Charles Manner
Hematology & Oncology Houston, TX Medical Doctor
NPI 1760443782 CMS profile 260834
2130 W Holcombe Blvd, 10Th Floor, Houston, TX 77030
General payments
$13,100
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Charles Manner of Houston, TX is reported in the CMS Open Payments database as having received $13,100 across 754 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 75th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $102 | 4 | |
| 2024 | General | $69 | 4 | |
| 2023 | General | $253 | 10 | |
| 2022 | General | $4,386 | 227 | |
| 2021 | General | $3,441 | 191 | |
| 2020 | General | $1,545 | 99 | |
| 2019 | General | $3,305 | 219 |
Beside peers
- Charles Manner
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Charles Manner were reported at $102. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Charles Manner | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,305 | $529 | $121–$2,516 | $163 |
| 2020 | $1,545 | $339 | $82–$2,213 | $114 |
| 2021 | $3,441 | $263 | $49–$1,965 | $132 |
| 2022 | $4,386 | $416 | $103–$2,395 | $149 |
| 2023 | $253 | $542 | $125–$2,646 | $160 |
| 2024 | $69 | $692 | $141–$3,008 | $164 |
| 2025 | $102 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
754 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Texas
Related records
Hematology & Oncology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.